The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against AChR (AChR+).
Thank you for your interest, but this study is not currently enrolling.
United States (Nationwide)
James Howard
Neurology-Neuromuscular
Clinical or Medical
Interventional
Chronic Conditions
23-0496
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
